PMID- 29851825
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 22
DP  - 2018 Jun
TI  - A pilot study of oral S-1 for treating heavily pretreated patients with advanced 
      or recurrent cervical cancer among Chinese population.
PG  - e10922
LID - 10.1097/MD.0000000000010922 [doi]
LID - e10922
AB  - This pilot study retrospectively aimed to assess the feasibility effectiveness 
      and safety of oral S-1 in heavily pretreated patients with advanced or recurrent 
      cervical cancer (ARCC) among Chinese population.Thirty patients with ARCC who had 
      undergone one or more lines of chemotherapy received oral S-1 (40-60 mg/m) twice 
      daily for 6 weeks. Outcome measurements included tumor response, time to 
      progression (TTP), overall survival (OS) time, and occurrence of adverse events 
      (AEs).The overall response rate was 43.3%. After a median follow-up of 6 months, 
      the median TTP was 4.4 months and the median OS time was 10.2 months. The most 
      frequent grade 3 or 4 AEs were neutropenia (13.3%) and nausea (16.7%).The results 
      of this study show that oral S-1 is effective and well-tolerated in patients with 
      ARCC who were heavily pretreated among Chinese population.
FAU - Ma, Li
AU  - Ma L
AD  - Department of Gynaecology and Obstetrics, Second Affiliated Hospital of 
      Mudanjiang Medical University Department of Oncology, The Affiliated Hongqi 
      Hospital of Mudanjiang Medical University Department of Anatomy, Mudanjiang 
      Medical University, Mudanjiang, China.
FAU - Liu, Jin-Miao
AU  - Liu JM
FAU - Zhang, Jing
AU  - Zhang J
FAU - Li, Hui
AU  - Li H
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Drug Combinations)
RN  - 150863-82-4 (S 1 (combination))
RN  - 1548R74NSZ (Tegafur)
RN  - 5VT6420TIG (Oxonic Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antimetabolites, Antineoplastic/*administration & dosage
MH  - China
MH  - Disease-Free Survival
MH  - Drug Combinations
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Oxonic Acid/*administration & dosage
MH  - Pilot Projects
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Tegafur/*administration & dosage
MH  - Treatment Outcome
MH  - Uterine Cervical Neoplasms/*drug therapy
MH  - Young Adult
PMC - PMC6392667
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/06/01 06:00
MHDA- 2018/06/12 06:00
PMCR- 2018/06/01
CRDT- 2018/06/01 06:00
PHST- 2018/06/01 06:00 [entrez]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
PHST- 2018/06/01 00:00 [pmc-release]
AID - 00005792-201806010-00053 [pii]
AID - MD-D-17-07669 [pii]
AID - 10.1097/MD.0000000000010922 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jun;97(22):e10922. doi: 10.1097/MD.0000000000010922.